Pfizer to acquire Seagen for $43bn.

Pfizer, an American multinational pharmaceutical and biotechnology corporation, agreed to acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $43bn. "Pfizer is deploying its financial resources to advance the battle against cancer, a leading cause of death worldwide with a significant impact on public health. Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate technology with the scale and strength of Pfizer’s capabilities and expertise. Oncology continues to be the largest growth driver in global medicine, and this acquisition will enhance Pfizer’s position in this important space and contribute meaningfully to the achievement of Pfizer’s near- and long-term financial goals," Albert Bourla, Pfizer Chairman and CEO.